Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition

 
• By Jessica Merrill

Chief scientific officer and president of Pfizer Research & Development Mikael Dolsten will depart the company after a successor is appointed, likely early next year.

Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer Inc.
Pfizer's Mikael Dolsten is leaving the company • Source: Pfizer (WENDY BARROWS photography)

More from Leadership

More from Scrip